Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS,  16/December/2017, 11.49 pm

Natural product-based therapy for Diabetic retinopathy: Notoginsenoside R1, isolated from Panax Notoginseng, inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 16/December/2017, 11.38 pm
December 16, 2017
Amino acid-based therapy for ageing-associated diseases and Lifespan extension: D-Serine increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 17/December/2017, 10.52 pm
December 17, 2017
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS

price-300


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides a natural product-based therapy for myocardial infarction. 

A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN), by increasing the expression of its target genes, it may increase the expression of PNUTS (figs.1-2)Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

Figure 1. Mechanistic insights into how a pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) induces the expression PNUTS and Telomerase to promote Cardiac regeneration/survival

Thus, by treating myocardial patients with Hypaphorine, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Pyridoxamine (PM) and Sulforaphane (SFN) or their analogues, either alone or in combination with any of the known drugs that improve myocardial function”  may be used to improve cardiac function after myocardial infarction (Fig. 1).  

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How a pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases the expression of PNUTS and Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L.,  Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS,  16/December/2017, 11.48 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.